{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:06:40Z","timestamp":1790136400112,"version":"4.0.1"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K27339"],"award-info":[{"award-number":["JP23K27339"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118439","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:23:03Z","timestamp":1788733383000},"page":"118439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Multilayered clearance concept: a membrane-resolved flux framework for drug metabolism"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-7646","authenticated-orcid":false,"given":"Hiroshi","family":"Arakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7871-3157","authenticated-orcid":false,"given":"Shengyu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.bcp.2026.118439_b0005","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.bcp.2026.118439_b0015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s11095-018-2524-0","article-title":"The extended clearance concept following oral and intravenous dosing: theory and critical analyses","volume":"35","author":"Benet","year":"2018","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.bcp.2026.118439_b0020","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1124\/dmd.123.001344","article-title":"A 20-year research overview: quantitative prediction of hepatic clearance using the in vitro-in vivo extrapolation approach based on physiologically based pharmacokinetic modeling and extended clearance concept","volume":"51","author":"Sugiyama","year":"2023","journal-title":"Drug Metab. Dispos."},{"issue":"11","key":"10.1016\/j.bcp.2026.118439_b0025","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1124\/dmd.117.077040","article-title":"Clearance prediction methodology needs fundamental improvement: trends common to rat and human hepatocytes\/microsomes and implications for experimental methodology","volume":"45","author":"Wood","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.bcp.2026.118439_b0030","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1007\/s00204-020-02765-8","article-title":"Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors","volume":"94","author":"Kasteel","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118439_b0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1208\/s12248-020-00482-9","article-title":"In vitro to in vivo extrapolation of metabolic clearance for UGT substrates using short-term suspension and long-term co-cultured human hepatocytes","volume":"22","author":"Docci","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.bcp.2026.118439_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108459","article-title":"Drug-drug interactions that alter the exposure of glucuronidated drugs: scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance","volume":"248","author":"Miners","year":"2023","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF01059626","article-title":"Clearance concepts in pharmacokinetics","volume":"1","author":"Rowland","year":"1973","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"6","key":"10.1016\/j.bcp.2026.118439_b0050","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/BF01059688","article-title":"Hepatic clearance of drugs. I. Theoretical considerations of a \u201cwell-stirred\u201d model and a \u201cparallel tube\u201d model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance","volume":"5","author":"Pang","year":"1977","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"4","key":"10.1016\/j.bcp.2026.118439_b0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1074-5521(03)00071-1","article-title":"Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition","volume":"10","author":"Bencharit","year":"2003","journal-title":"Chem. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0060","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jmb.2007.03.066","article-title":"Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7","volume":"369","author":"Miley","year":"2007","journal-title":"J. Mol. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118439_b0065","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.bbamem.2007.03.009","article-title":"Transport and transporters in the endoplasmic reticulum","volume":"1768","author":"Csala","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.bcp.2026.118439_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16091167","article-title":"Subcellular drug distribution: exploring organelle-specific characteristics for enhanced therapeutic efficacy","volume":"16","author":"Liu","year":"2024","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics9030032","article-title":"Revisiting the latency of uridine diphosphate-glucuronosyltransferases (UGTs) \u2013 how does the endoplasmic reticulum membrane influence their function?","volume":"9","author":"Liu","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2026.118439_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116322","article-title":"Endoplasmic reticulum transporter OAT2 regulates drug metabolism and interaction","volume":"225","author":"Arakawa","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"Pt 1","key":"10.1016\/j.bcp.2026.118439_b0085","article-title":"Role of organic anion transporter 2 in the efflux of raltegravir glucuronide from the endoplasmic reticulum in the liver","volume":"242","author":"Dai","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0090","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1124\/mol.118.114934","article-title":"OATP1B3-1B7 (LST-3TM12) is a drug transporter that affects endoplasmic reticulum access and the metabolism of ezetimibe","volume":"96","author":"Malagnino","year":"2019","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0095","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.123.001487","article-title":"PBPK modelling for drugs cleared by non-CYP enzymes: state-of-the-art and future perspectives","volume":"52","author":"Ozbey","year":"2023","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrm2330","article-title":"Membrane lipids: where they are and how they behave","volume":"9","author":"van Meer","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7503","key":"10.1016\/j.bcp.2026.118439_b0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nature13474","article-title":"Lipid landscapes and pipelines in membrane homeostasis","volume":"510","author":"Holthuis","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2026.118439_b0110","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.bbalip.2013.11.014","article-title":"MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond","volume":"1841","author":"Vance","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0115","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41467-019-09253-3","article-title":"Coming together to define membrane contact sites","volume":"10","author":"Scorrano","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2133\/dmpk.DMPK-13-RG-096","article-title":"Extensive protein-protein interactions involving UDP-glucuronosyltransferase (UGT) 2B7 in human liver microsomes","volume":"29","author":"Fujiwara","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"6947","key":"10.1016\/j.bcp.2026.118439_b0125","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature01862","article-title":"Crystal structure of human cytochrome P450 2C9 with bound warfarin","volume":"424","author":"Williams","year":"2003","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0130","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1152\/physrev.00025.2023","article-title":"The ion channels of endomembranes","volume":"104","author":"Hu","year":"2024","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bcp.2026.118439_b0135","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.csbj.2019.08.002","article-title":"Nucleotide sugar transporter SLC35 family structure and function","volume":"17","author":"Hadley","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/ars.2009.2529","article-title":"Redox control of endoplasmic reticulum function","volume":"13","author":"Csala","year":"2010","journal-title":"Antioxid. Redox Signal."},{"issue":"9","key":"10.1016\/j.bcp.2026.118439_b0145","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.tibs.2011.05.004","article-title":"Multiple ways to make disulfides","volume":"36","author":"Bulleid","year":"2011","journal-title":"Trends Biochem. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/abbi.1998.0750","article-title":"Determinants of UDP glucuronosyltransferase membrane association and residency in the endoplasmic reticulum","volume":"356","author":"Meech","year":"1998","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2026.118439_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107414","article-title":"The UGTome: the expanding diversity of UDP glycosyltransferases and its impact on small molecule metabolism","volume":"204","author":"Hu","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0160","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/mol.104.006361","article-title":"Coimmunoprecipitation of UDP-glucuronosyltransferase isoforms and cytochrome P450 3A4","volume":"67","author":"Fremont","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0165","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/mol.104.007641","article-title":"Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4","volume":"67","author":"Takeda","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0170","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.113.054833","article-title":"Alteration of the function of the UDP-glucuronosyltransferase 1A subfamily by cytochrome P450 3A4: different susceptibility for UGT isoforms and UGT1A1\/7 variants","volume":"42","author":"Ishii","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2026.118439_b0175","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fphar.2016.00388","article-title":"Structure and protein-protein interactions of human UDP-glucuronosyltransferases","volume":"7","author":"Fujiwara","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.dmpk.2014.12.001","article-title":"A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development","volume":"30","author":"Oda","year":"2015","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2026.118439_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116128","article-title":"Role of carboxylesterase and arylacetamide deacetylase in drug metabolism, physiology, and pathology","volume":"223","author":"Nagaoka","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2015.07.071","article-title":"Microsomal epoxide hydrolase 1 (EPHX1): gene, structure, function, and role in human disease","volume":"571","author":"V\u00e1clav\u00edkov\u00e1","year":"2015","journal-title":"Gene"},{"issue":"5","key":"10.1016\/j.bcp.2026.118439_b0195","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1210\/er.2003-0031","article-title":"11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response","volume":"25","author":"Tomlinson","year":"2004","journal-title":"Endocr. Rev."},{"issue":"6974","key":"10.1016\/j.bcp.2026.118439_b0200","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature02214","article-title":"Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2","volume":"427","author":"Rost","year":"2004","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0205","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1042\/BST20190257","article-title":"Catalytic mechanism of UDP-glucose dehydrogenase","volume":"47","author":"Chen","year":"2019","journal-title":"Biochem. Soc. Trans."},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0210","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0022-3565(25)38967-6","article-title":"Depletion of hepatic UDP-glucuronic acid by drugs that are glucuronidated","volume":"236","author":"Howell","year":"1986","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2026.118439_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113916","article-title":"SLC35B1 significantly contributes to the uptake of UDPGA into the endoplasmic reticulum for glucuronidation catalyzed by UDP-glucuronosyltransferases","volume":"175","author":"Ondo","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"16","key":"10.1016\/j.bcp.2026.118439_b0220","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.csbj.2014.05.003","article-title":"Structure and function of nucleotide sugar transporters: current progress","volume":"10","author":"Hadley","year":"2014","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0225","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/BJ20060429","article-title":"Molecular and functional characterization of microsomal UDP-glucuronic acid uptake by members of the nucleotide sugar transporter (NST) family","volume":"400","author":"Kobayashi","year":"2006","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0230","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0016-5085(95)90023-3","article-title":"Membrane translocation and regulation of uridine diphosphate-glucuronic acid uptake in rat liver microsomal vesicles","volume":"108","author":"Berg","year":"1995","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0235","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0005-2736(96)00098-3","article-title":"Two kinetically-distinct components of UDP-glucuronic acid transport in rat liver endoplasmic reticulum","volume":"1283","author":"Battaglia","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/dmd.114.060509","article-title":"Transporter-mediated uptake of UDP-glucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition","volume":"43","author":"Rowland","year":"2015","journal-title":"Drug Metab. Dispos."},{"issue":"16","key":"10.1016\/j.bcp.2026.118439_b0245","doi-asserted-by":"crossref","first-page":"10852","DOI":"10.1074\/jbc.274.16.10852","article-title":"Unconjugated bilirubin exhibits spontaneous diffusion through model lipid bilayers and native hepatocyte membranes","volume":"274","author":"Zucker","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"26","key":"10.1016\/j.bcp.2026.118439_b0250","doi-asserted-by":"crossref","first-page":"23492","DOI":"10.1074\/jbc.M102494200","article-title":"A unique multifunctional transporter translocates estradiol-17beta -glucuronide in rat liver microsomal vesicles","volume":"276","author":"Battaglia","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0255","doi-asserted-by":"crossref","first-page":"413","DOI":"10.18388\/abp.2011_2255","article-title":"Subcellular localization of UDP-GlcNAc, UDP-Gal and SLC35B4 transporters","volume":"58","author":"Maszczak-Seneczko","year":"2011","journal-title":"Acta Biochim. Pol."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2026.118439_b0260","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0014-5793(01)02358-4","article-title":"Molecular characterization of human UDP-glucuronic acid\/UDP-N-acetylgalactosamine transporter, a novel nucleotide sugar transporter with dual substrate specificity","volume":"495","author":"Muraoka","year":"2001","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0265","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/dmd.116.072264","article-title":"Organic anion transporter 2: an enigmatic human solute carrier","volume":"45","author":"Shen","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2026.118439_b0270","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bcp.2017.12.012","article-title":"LST-3TM12 is a member of the OATP1B family and a functional transporter","volume":"148","author":"Malagnino","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118439_b0275","doi-asserted-by":"crossref","first-page":"G751","DOI":"10.1152\/ajpgi.00330.2018","article-title":"OATP1B3-1B7, a novel organic anion transporting polypeptide, is modulated by FXR ligands and transports bile acids","volume":"317","author":"Malagnino","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0280","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1254\/jphs.10228SC","article-title":"Functional analysis of human sodium-phosphate transporter 4 (NPT4\/SLC17A3) polymorphisms","volume":"115","author":"Jutabha","year":"2011","journal-title":"J. Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.118439_b0285","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1023\/B:BOLI.0000045755.89308.2f","article-title":"NPT4, a new microsomal phosphate transporter: mutation analysis in glycogen storage disease type Ic","volume":"27","author":"Melis","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0290","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.106.013359","article-title":"Misuse of the well-stirred model of hepatic drug clearance","volume":"35","author":"Yang","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"5 Pt 2","key":"10.1016\/j.bcp.2026.118439_b0295","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/cpt1977225part2623","article-title":"Theoretic aspects of pharmacokinetic drug interactions","volume":"22","author":"Gillette","year":"1977","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0300","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.abb.2013.03.012","article-title":"Evaluation of UGT protein interactions in human hepatocytes: effect of siRNA down regulation of UGT1A9 and UGT2B7 on propofol glucuronidation in human hepatocytes","volume":"535","author":"Konopnicki","year":"2013","journal-title":"Arch. Biochem. Biophys."},{"issue":"11","key":"10.1016\/j.bcp.2026.118439_b0305","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1124\/dmd.123.001369","article-title":"Heterodimerization of human UDP-glucuronosyltransferase 1A9 and UDP-glucuronosyltransferase 2B7 alters their glucuronidation activities","volume":"51","author":"Xue","year":"2023","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bcp.2026.118439_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100229","article-title":"Overlooked aspects of scaling enzyme activity through abundance across tissues and individuals: insights from kcat measurements in matched liver and intestinal samples","volume":"54","author":"Al-Majdoub","year":"2026","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0315","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","article-title":"Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption","volume":"34","author":"Shitara","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"issue":"5","key":"10.1016\/j.bcp.2026.118439_b0320","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0090-9556(25)06808-4","article-title":"Glucuronidation in vitro and in vivo. comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine","volume":"15","author":"Mistry","year":"1987","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0325","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.301.1.382","article-title":"In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance","volume":"301","author":"Soars","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0330","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1124\/dmd.108.023853","article-title":"Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes","volume":"37","author":"Kilford","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.bcp.2026.118439_b0335","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2133\/dmpk.DMPK-13-RG-105","article-title":"Evaluation of human hepatocytes cultured by three-dimensional spheroid systems for drug metabolism","volume":"29","author":"Ohkura","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2026.118439_b0340","doi-asserted-by":"crossref","first-page":"25187","DOI":"10.1038\/srep25187","article-title":"Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease","volume":"6","author":"Bell","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0345","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s42003-023-05216-z","article-title":"Induction of open-form bile canaliculus formation by hepatocytes for evaluation of biliary drug excretion","volume":"6","author":"Arakawa","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bcp.2026.118439_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2026.111931","article-title":"In vitro recapitulation of drug metabolite partitioning into the bile and blood using the icHep system consisting of hepatocytes with an induced open-form bile canaliculus","volume":"427","author":"Nakazono","year":"2026","journal-title":"Chem. Biol. Interact."},{"issue":"5","key":"10.1016\/j.bcp.2026.118439_b0355","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/cpt.2482","article-title":"Can in vitro-in vivo extrapolation be successful? Recognizing the incorrect clearance assumptions","volume":"111","author":"Benet","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118439_b0360","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1146\/annurev.pharmtox.44.101802.121444","article-title":"Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs","volume":"45","author":"Shitara","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118439_b0365","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s12272-017-0976-0","article-title":"Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling","volume":"40","author":"Min","year":"2017","journal-title":"Arch. Pharm. Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118439_b0370","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70299","article-title":"Drug interaction PBPK modeling: review of the literature exposes the need for increased verification of model inputs and outputs as part of credibility assessment","volume":"18","author":"Rodrigues","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bcp.2026.118439_b0375","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.910789","article-title":"A quantitative systems pharmacology model of liver lipid metabolism for investigation of non-alcoholic fatty liver disease","volume":"13","author":"Rieger","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118439_b0380","article-title":"Introduction to single-cell physiologically-based pharmacokinetic (scPBPK) models","author":"Saini","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.bcp.2026.118439_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2026.101526","article-title":"UDP-Glucuronosyl transferase mediated drug-drug interactions: an industry perspective on recommended in vitro studies","volume":"67","author":"Stresser","year":"2026","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0390","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/dmdi-2015-0003","article-title":"Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins","volume":"30","author":"Kunze","year":"2015","journal-title":"Drug Metab. Pers. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0395","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2125.2011.03947.x","article-title":"Effect of atazanavir and atazanavir\/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S\/GSK1349572","volume":"72","author":"Song","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0460","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0400","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bcpt.13538","article-title":"Drug-drug interaction of atazanavir on UGT1A1-mediated glucuronidation of molidustat in human","volume":"128","author":"van der Mey","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0405","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1086\/588794","article-title":"Atazanavir modestly increases plasma levels of raltegravir in healthy subjects","volume":"47","author":"Iwamoto","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.bcp.2026.118439_b0465","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3851\/IMP1673","article-title":"Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals","volume":"15","author":"Zhu","year":"2010","journal-title":"Antivir. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2026.118439_b0470","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1128\/AAC.00712-10","article-title":"Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers","volume":"54","author":"Neely","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.bcp.2026.118439_b0475","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/FTD.0b013e3181fa53b7","article-title":"Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients","volume":"32","author":"Cattaneo","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bcp.2026.118439_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106309","article-title":"Assessing the contribution of UGT isoforms on raltegravir drug disposition through PBPK modeling","volume":"179","author":"Moreira","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118439_b0485","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jcph.418","article-title":"Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers","volume":"55","author":"Joseph","year":"2015","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0490","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1124\/jpet.114.218081","article-title":"Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients","volume":"351","author":"Sane","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.bcp.2026.118439_b0435","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/annonc\/mdm366","article-title":"A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan","volume":"18","author":"Midgley","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.118439_b0495","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2017.01.002","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia","volume":"129","author":"Miners","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118439_b0500","doi-asserted-by":"crossref","first-page":"17778","DOI":"10.1038\/srep17778","article-title":"Drug-drug interaction potentials of tyrosine kinase inhibitors via inhibition of UDP-glucuronosyltransferases","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0440","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10637-014-0142-1","article-title":"A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer","volume":"33","author":"Bennouna","year":"2015","journal-title":"Invest. New Drugs"},{"issue":"5","key":"10.1016\/j.bcp.2026.118439_b0505","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00280-019-03784-8","article-title":"Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38","volume":"83","author":"Iwase","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118439_b0445","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/annonc\/mdt056","article-title":"Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study","volume":"24","author":"Schultheis","year":"2013","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0450","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2006.08.032","article-title":"Results from an in vitro and a clinical\/pharmacological phase I study with the combination irinotecan and sorafenib","volume":"43","author":"Mross","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2026.118439_b0510","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/0091270006289848","article-title":"Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs","volume":"46","author":"Khosravan","year":"2006","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118439_b0515","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40262-016-0466-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of febuxostat","volume":"56","author":"Kamel","year":"2017","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.bcp.2026.118439_b0520","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/bdd.1933","article-title":"Screening of non-steroidal anti-inflammatory drugs for inhibitory effects on the activities of six UDP-glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using LC-MS\/MS","volume":"36","author":"Joo","year":"2015","journal-title":"Biopharm. Drug Dispos."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2026.118439_b0525","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2003.09.008","article-title":"Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy","volume":"57","author":"Gidal","year":"2003","journal-title":"Epilepsy Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118439_b0530","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0535","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0022-3565(25)23469-3","article-title":"Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation","volume":"234","author":"Abernethy","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0540","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00008571-199202000-00007","article-title":"Variability of acetaminophen metabolism in Caucasians and Orientals","volume":"2","author":"Patel","year":"1992","journal-title":"Pharmacogenetics"},{"issue":"11","key":"10.1016\/j.bcp.2026.118439_b0545","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.2600711114","article-title":"Pharmacokinetics of probenecid following oral doses to human volunteers","volume":"71","author":"Selen","year":"1982","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118439_b0550","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0415","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/dom.12024","article-title":"Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin","volume":"15","author":"Kasichayanula","year":"2013","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0420","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/psp4.12581","article-title":"Physiologically-based pharmacokinetic modeling of the drug-drug interaction of the UGT substrate ertugliflozin following co-administration with the UGT inhibitor mefenamic acid","volume":"10","author":"Callegari","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118439_b0555","series-title":"Report on the Deliberation Results Forxiga 5 mg tablets, Forxiga 10 mg tablets","author":"Pharmaceuticals","year":"2014"},{"issue":"5","key":"10.1016\/j.bcp.2026.118439_b0560","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/BF00558077","article-title":"Pharmacokinetic interaction between indomethacin and diflunisal","volume":"36","author":"Van Hecken","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118439_b0565","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2125.2011.04136.x","article-title":"Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects","volume":"73","author":"Langdon","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0570","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/pharmaceutics15020679","article-title":"A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug-drug interaction perpetrators","volume":"15","author":"Marok","year":"2023","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.bcp.2026.118439_b0575","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1124\/dmd.106.009738","article-title":"Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode","volume":"34","author":"Takeda","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0580","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0009-9236(96)90019-3","article-title":"Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine","volume":"59","author":"Lee","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2026.118439_b0585","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1208\/s12248-020-00513-5","article-title":"Construction and verification of physiologically based pharmacokinetic models for four drugs majorly cleared by glucuronidation: lorazepam, oxazepam, naloxone, and zidovudine","volume":"22","author":"Docci","year":"2020","journal-title":"AAPS J."},{"issue":"7","key":"10.1016\/j.bcp.2026.118439_b0590","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1128\/AAC.42.7.1592","article-title":"Glucuronidation of 3'-azido-3'-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid","volume":"42","author":"Trapnell","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.bcp.2026.118439_b0595","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/infdis\/169.5.1103","article-title":"Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus","volume":"169","author":"Sahai","year":"1994","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2026.118439_b0600","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation","volume":"61","author":"Uchaipichat","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118439_b0605","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00042560-199808150-00004","article-title":"Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262)","volume":"18","author":"McCance-Katz","year":"1998","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0610","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1124\/jpet.110.167916","article-title":"In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans","volume":"334","author":"Raungrut","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0455","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/clpt.1994.137","article-title":"Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus","volume":"56","author":"Lertora","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2026.118439_b0615","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0006-2952(03)00076-5","article-title":"The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases","volume":"65","author":"Ethell","year":"2003","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118439_b0430","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/clpt.1989.176","article-title":"Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex","volume":"46","author":"de Miranda","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8661","key":"10.1016\/j.bcp.2026.118439_b0620","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(89)92087-4","article-title":"Probenecid and zidovudine metabolism","volume":"2","author":"Kornhauser","year":"1989","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2026.118439_b0625","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2125.1991.tb05607.x","article-title":"The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes","volume":"32","author":"Sim","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0630","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/bdd.2510140204","article-title":"Inhibition of acetaminophen and lorazepam glucuronidation in vitro by probenecid","volume":"14","author":"von Moltke","year":"1993","journal-title":"Biopharm. Drug Dispos."},{"issue":"2","key":"10.1016\/j.bcp.2026.118439_b0635","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0378-4347(93)80395-K","article-title":"Determination of indomethacin, its metabolites and their glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis. Preliminary pharmacokinetics and effect of probenecid","volume":"616","author":"Vree","year":"1993","journal-title":"J. Chromatogr."},{"issue":"5","key":"10.1016\/j.bcp.2026.118439_b0640","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1124\/dmd.109.031252","volume":"38","author":"Vourvahis","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bcp.2026.118439_b0645","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/cpt1976203329","article-title":"Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam","volume":"20","author":"Greenblatt","year":"1976","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118439_b0650","unstructured":"GlaxoSmithKline, Mepron\u00ae (atovaquone) oral suspension prescribing information, 2008. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020500s010lbl.pdf."},{"issue":"11","key":"10.1016\/j.bcp.2026.118439_b0410","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1124\/dmd.105.005447","article-title":"In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.bcp.2026.118439_b0425","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1021\/mp4001348","article-title":"Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia","volume":"10","author":"Chang","year":"2013","journal-title":"Mol. Pharm."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:40:14Z","timestamp":1790134814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226007781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":130,"alternative-id":["S0006295226007781"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118439","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multilayered clearance concept: a membrane-resolved flux framework for drug metabolism","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118439"}}